Results 151 to 160 of about 26,895 (263)

SGLT2 inhibitor therapy and clinical outcomes in HIV-related cardiomyopathy. [PDF]

Am Heart J Plus
Sheashaa H, Ibrahim R, Pham HN, Awad K, Scalia IG, Farina JM, Tamarappoo B, Holloway C, Arsanjani R, Ayoub C.   +9 more
europepmc   +1 more source

T2D Management Among a Community Clinic Patient Sample After California's May 2022 Medicaid Expansion

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims In May 2022, California expanded its Medicaid program (‘Medi‐Cal’) to all low‐income adults over 50 years, regardless of immigration status. We compare haemoglobin A1c (HbA1c) and body mass index (BMI) among undocumented patients with Type 2 diabetes mellitus (T2D) in a primary care setting before and after the expansion.
Annie E. Ro, Jung Min Choi, Celina Morales, Nicole Tavares Kuhn, Cecilia Wu, Luohua Jiang   +5 more
wiley   +1 more source

From glucosuria to dialysis: a case report of osmotic nephropathy due to an SGLT2 inhibitor. [PDF]

BMC Nephrol
Castellanos-de la Hoz J, Molano-Triviño A, González-García YF, Espinosa Saltaren LM, Zúñiga-Rodríguez E.   +4 more
europepmc   +1 more source

Aerobic Exercise Training Increases Circulating sRAGE in Adults With Type 2 Diabetes: Associations With Sheddase Regulation

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Objective Soluble receptor for advanced glycation end‐products (sRAGE) and soluble Toll‐like receptor 4 (sTLR4) are circulating pattern recognition receptor isoforms implicated in inflammatory regulation in type 2 diabetes mellitus (T2DM). This study examined the effects of supervised aerobic exercise training (AET) on circulating sRAGE, sTLR4,
Ryan K. Perkins, Corey E. Mazo, James Shadiow, Pallavi Varshney, Edwin R. Miranda, Victoria R. Miranda, Maggie Eisenberg, Jane E. Nakamura, Elif A. Oral, Jacob M. Haus   +9 more
wiley   +1 more source

Barriers to SGLT2 inhibitor prescribing in primary care: findings from a cross-sectional questionnaire study in England. [PDF]

Clin Kidney J
Dattani R, Purssell N, Desilva R, Joshi M, Frankel AH, Ashrafian H, Darzi A, Tam FWK.   +7 more
europepmc   +1 more source

The SGLT2 inhibitor checklist: a comprehensive review of perioperative and acute phase safety management. [PDF]

Front Endocrinol (Lausanne)
Deng B, Liu W, Chu Q.
europepmc   +1 more source

Prescribing Trajectories in Type 2 Diabetes in the United States, 2019–2024

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Importance Clinical guidelines for type 2 diabetes (T2D) provide population‐level recommendations, but real‐world treatment patterns evolve dynamically and vary across patients. Understanding longitudinal prescribing trajectories may reveal heterogeneity in care not captured by cross‐sectional analyses.
Tobias S. Lux, Dongkun Lee, Jeff M. Phillips, Julio C. Facelli, Daniel C. Malone, Matthew Wahl, Deepika Reddy, Farrant Sakaguchi, Ramkiran Gouripeddi, Alexander S. Millar, Matthew J. O'Brien, Joshua S. Choi, Jittrapol Sutejitsiri, Kensaku Kawamoto, Polina V. Kukhareva   +14 more
wiley   +1 more source

Current practices of SGLT2 inhibitor use and ketone monitoring in intensive care units: A multicentre observational study. [PDF]

Crit Care Resusc
Sasaki T, Micallef S, Wang AY, Butt F, Hammond NE, Hardie M, Knowles S, Yokoo T, Gallagher M, George Institute for Global Health and the Australian and New Zealand Intensive Care Society Clinical Trials Group.   +9 more
europepmc   +1 more source

Diagnosis and management of equine metabolic syndrome

Equine Veterinary Education, EarlyView.
Summary Equine metabolic syndrome (EMS) is a prevalent endocrine disorder that increases the risk of hyperinsulinaemia‐associated laminitis (HAL), the most common and clinically significant form of laminitis. The central pathological feature of EMS is insulin dysregulation (ID), which encompasses basal or postprandial hyperinsulinaemia and tissue ...
F. R. Bertin
wiley   +1 more source

Caring for Australians and New ZealandeRs with kidney Impairment guideline commentary on kidney disease: improving global outcomes 2025 guidelines for diagnosis and management of autosomal polycystic kidney disease

Internal Medicine Journal, EarlyView.
Abstract Autosomal polycystic kidney disease (ADPKD) is the most common form of inherited kidney disease. The international guideline developer, Kidney Disease: Improving Global Outcomes (KDIGO), published a 2025 clinical practice guideline reflecting advances in genetic testing and the first disease‐modifying agent, tolvaptan.
Mia E. Abdy, Kitty St Pierre, Emily Major, Stephen I. Alexander, Brydee Cashmore, Helen Coolican, Vanessa Cullen, Jessica Dawson, Kelly Lambert, Vincent W. Lee, Amali Mallawaarachi, Gopala Rangan, Judy Savige, Santosh Varughese, David J. Tunnicliffe, Andrew J. Mallett, on behalf of the CARI Guidelines Steering Committee, Emily See, Leanne Brown, Jonathan Craig, Jeffrey Ha, Rathika Krishnasamy, Casey Light, Emmy O'Neill, Thu Nguyen, Hannah Smith, Andrea Viecelli   +26 more
wiley   +1 more source